Tina Q Tan, MD, and Kimberly Simmons, MD, provide an overview of the prevalence of type 1 diabetes (T1D) in pediatric patients as well as its risk factors.
Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.
ISPAD, EASD, and ADA urge pediatric diabetes teams to build center-specific transition policies, use readiness checklists, and ensure timely handoffs to adult clinicians.